Editing of ADA2 Point Mutation in Human Hematopoietic Stem Cells
Authors:
- Pavel KopcilPKPavel Kopcil
- Carolina W. ErvikCECarolina W. Ervik
- Ganna ReintGRGanna Reint
- Katariina MamiaKMKatariina Mamia
- Monika SzymanskaMSMonika Szymanska
- Shiva Dahal-KoiralaSDShiva Dahal-Koirala
- Jacob ConradiJCJacob Conradi
- Sigrid Fu SkjelbostadSSSigrid Fu Skjelbostad
- Oda A. DønåsenODOda A. Dønåsen
- Xiaojun JiangXJXiaojun Jiang
- Cecilia Fahlquist-HagertCFCecilia Fahlquist-Hagert
- Oddrun KristiansenOKOddrun Kristiansen
Preprint
Abstract
Background: The homozygous ADA2 : c.506G>A (p.Arg169Gln; p.R169Q) variant accounts for majority of Deficiency in Adenosine Deaminase 2 (DADA2). This monogenic disorder may be amenable to ex vivo gene therapy by correcting the pathogenic mutation in CD34+ hematopoietic stem and progenitor cells (HSPCs). Objective: To apply CRISPR-Cas9 and homology-directed repair (HDR) as a surrogate strategy to model correction of the pathogenic ADA2 c.506G>A variant in healthy cord blood HSPCs. Methods: HSPCs were electroporated with optimised CRISPR-Cas9 editing reagents, and editing outcomes, including HDR and on-target deletions, were quantified by ddPCR. Cell functionality was assessed through colony-forming unit (CFU) assays and by xenotransplantation into NOD SCID Gamma (NSG) mice. Two HDR enhancement strategies were tested: (1) genetic inhibitors of p53 and non-homologous end joining (NHEJ) pathways, and (2) pharmacological NHEJ inhibition. Results: Small-molecule NHEJ inhibitors increased HDR efficiency approximately two-fold (from ∼40 % to ∼80 %). Edited HSPCs retained normal CFU capacity and successfully engrafted in NSG mice. However, up to 8 % of edited cells exhibited on-target chromosome loss, though this declined over time. Up to 40 % of T cells and fibroblasts demonstrated similar losses under NHEJ inhibitors treatment. In contrast, genetically encoded inhibitors did not improve HDR. Conclusion: The ADA2 p. c.506G>A variant can be effectively edited employing surrogate strategy in HSPCs without impairing functionality. Although pharmacological inhibition of NHEJ enhances HDR efficiency, it also increases the risk of on-target chromosome aberrations, highlighting the need for careful consideration of the associated risks and benefits in therapeutic gene editing. Key messages: 1) The ADA2 p.R169Q variant can be efficiently corrected via HDR, and the edited CD34+ HSPCs retain their engraftment capability in NSG mice. 2) Pharmacological inhibition of NHEJ using small-molecule inhibitors increases HDR efficiency but is associated with significant on-target deletions and chromosomal arm loss, particularly in differentiated cell types, and in a donor-dependent manner. Capsule summary: The ADA2 p.R169Q variant is a viable target for precision gene editing in hematopoietic stem cells. Although inhibition of NHEJ improves HDR efficiency, it concomitantly increases the risk of large on-target deletions, particularly in differentiated cells.Keywords
This publication has 75 references indexed in Scilit:
- Human ADA2 Deficiency: Ten Years LaterCurrent Allergy and Asthma Reports, 2024
- Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cellsCell, 2023
- Prediction of efficiencies for diverse prime editing systems in multiple cell typesCell, 2023
- Cas9‐Geminin and Cdt1‐fused anti‐CRISPR protein synergistically increase editing accuracyFEBS Letters, 2023
- Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cellsFEBS Open Bio, 2021
- Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approachJournal of Allergy and Clinical Immunology, 2021
- Persistence of CRISPR/Cas9 Gene Edited Hematopoietic Stem Cells Following Transplantation: A Systematic Review and Meta-Analysis of Preclinical StudiesStem Cells Translational Medicine, 2021
- Severe Congenital Neutropenia associated with SRP54 mutation in 22q11.2 Deletion Syndrome: Hematopoietic Stem Cell Transplantation Results in Correction of Neutropenia with Adequate Immune ReconstitutionJournal of Clinical Immunology, 2018
- Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and TreatmentJournal of Clinical Immunology, 2018
- ADA2 deficiency: Clonal lymphoproliferation in a subset of patientsJournal of Allergy and Clinical Immunology, 2018